谭焕然
人物履历
毕业于北京医学院（北京大学医学部）基础医学专业。多年来一直从事基因和分子生物学以及分子药理学方面的研究工作。1991年作为访问学者在著名的分子生物学研究中心美国冷泉港实验室(Cold Spring Harbor Laboratory, New York, USA)进修。承担细胞周期中具有重要作用的转录因子的研究课题，完成了这些因子的克隆、表达及功能的研究。1995年又曾以访问学者的身份前往美国康奈尔大学医学院附属北岸医院研究中心，运用RDA（Representational Difference Analysis）技术和基因差异显示技术（Differential Display），筛选肿瘤细胞分裂过程中的关键新基因。1997年回国后，在北京大学医学部基础医学院药理学系建立了具有一定规模的分子药理学研究室。开展了与疾病有关的基因缺陷的动物模型的建立与研究工作，同时还涉及离子通道、分子肿瘤及心血管分子药理学等方面研究工作。、
研究方向
（1）采用基因敲除、基因敲入及转基因等研究方法研究和建立疾病动物模型和药理学研究模型；
（2）糖尿病和降血糖药物的分子作用机制研究；
（3）抗肿瘤药物及肿瘤发病机制的研究。
科研项目
国家十一五支撑计划（2015.07.01-2017.12.31）；
课题名称：科研用试剂产业链创新体系的构建
课题编号：2015BAK45B01
任务名称：制剂产品的抗原物质检测试剂盒研发及关键技术的研究
任务负责人：谭焕然
国家自然科学基金面上项目（2017.1.1-2020.12.31）
课题名称：巨噬细胞介导的肿瘤转移分子机制及潜在药物作用靶点的研究
项目编号：81673459/H3105
项目负责人：谭焕然
学术成果
文章
1 Hui Li, Yiqing Mao, Qun Zhang, Qing Han, Zhenming Man, Jingyu Zhang, Xi Wang, Ruobi Hu, Xuehui Zhang, David M Irwin*, Gang Niu*, Huanran Tan*, Xinmailong mitigated epirubicin-induced cardiotoxicity via inhibiting autophagy，Journal of Ethnopharmacology 2016，192，459–470 http://dx.doi.org/10.1016/j.jep.2016.08.031 （IF= 3.055）
2 Na Zhou, Yizhuang Zhang, Xuehui Zhang, Zhen Lei, Ruobi Hu, Hui Li, Yiqing Mao, Xi Wang, David M. Irwin,* Gang Ni*, and Huanran Tan,* Exposure of Tumor-Associated Macrophages to Apoptotic MCF-7 Cells Promotes Breast Cancer Growth and Metastasis International Journal of Molecular Sciences. Int. J. Mol. Sci. 2015, 16, 11966-11982; doi:10.3390/ijms160611966 ( IF=2.339 5 year IF=2.721)
3 Na Zhou, Rong Wang（共同第一作者）, Yizhuang Zhang, Zhen Lei, Xuehui Zhang, Ruobi Hu, Hui Li, Yiqing Mao, Xi Wang, David M. Irwin*, Gang Niu*, Huanran Tan,*Staurosporine induced apoptosis may activate cancer stem-like cells (CD44+/CD24-) in MCF-7 by upregulating mucin1 and EpCAM. Journal of Cancer 2015; 6(10): 1049-1057. doi: 10.7150/jca.12501 ( IF=3.271)
4 Ling Jin, Tingting Guo, Zhixin Li , Zhen Lei, Hui Li, Yiqing Mao, Xi Wang , Na Zhou, Yizhuang Zhang, Ruobi Hu, Xuehui Zhang, Gang Niu ,* David M. Irwin,* and Huanran Tan,*Role of Glucokinase in the Subcellular Localization of Glucokinase Regulatory Protein. International Journal of Molecular Sciences. Int. J. Mol. Sci. 2015, 16, 7377-7393; doi:10.3390/ijms16047377 ( IF=2.339 5 year IF=2.721)
5 Hui Li, Xi Wang, Yiqing Mao, Ruobi Hu, Wei Xu, Zhen Lei, Na Zhou, Ling Jin, Tingting Guo, Zhixin Li, David M Irwin, Gang Niu* and Huanran Tan*, Long term liver specific glucokinase gene defect induced diabetic cardiomyopathy by up regulating NADPH oxidase and down regulating insulin receptor and p-AMPK. Cardiovascular Diabetology 2014,13(24).doi:10.1186/1475- 2840-13-24 ( IF=4.209，5 year IF=3.774)
6 Rong Wang, Hui Gao, Wei Xu, Hui Li, Yiqing Mao, Yi Wang, Tingting Guo, Xi Wang, Rongjing Song, Zhixin Li, David M. Irwina, Gang Niu and Huanran Tan.* Differential expression of genes and changes in glucose metabolism in the liver of liver-specific glucokinase gene knockout mice Gene 2013 516: 248-254 (IF=2.341, 5 years IF=2.443)
7 Xiaojing Zhang, Hui Li, Yiqing Mao, Zhixin Li, Rong Wang, Tingting Guo, Ling Jin, Rongjing Song, Wei Xu, Na Zhou, Yizhuang Zhang, Ruobi Hu, Xi Wang, Huakang Huang, Zhen Lei, Gang Niu, David M. Irwin，Huanran Tan*, An over expression APP model for anti-Alzheimer disease drug screening created by Zinc Finger Nuclease Technology. PLoS ONE8(11): e75493 doi:10.1371 / journal. pone. 0075493 ( IF=4.092，5 year IF=4.537)
8 Wei Xu, Hui Li, Rong Wang, Zhen Lei, Yiqing Mao, Xi Wang, Yizhuang Zhang, Tingting Guo, Rongjing Song, Xiaojing Zhang, Ling Jin, Zhixin Li, David M. Irwin*, Gang Niu, Huanran Tan*, Differential Expression of Genes Associated with the Progression of Renal Disease in the Kidneys of Liver-Specific Glucokinase Gene Knockout Mice. Int. J. Mol. Sci.( International Journal of Molecular Sciences) 2013, 14, 6467-6486; doi:10.3390/ijms14036467 ( IF=2.598，5 year IF=2.617 )
9 Rongjing Song, Xi Wang, Yiqing Mao, Hui Li, Zhixin Li, Wei Xu, Rong Wang, Tingting Guo, Ling Jin, Xiaojing Zhang, Yizhuang Zhang, Na Zhou, Ruobi Hu, Jianwei Jia, Zhen Lei, David M. Irwin, Gang Niu, Huanran Tan*, Resistin disrupts glycogen synthesis under high insulin and high glucose levels by down-regulating the hepatic levels of GSK3β 2013. Gene 529 (2013) 50–56(IF=2.341, 5 years IF=2.443)[1]